Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ: GH )

47.41 +1.77 (+3.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
68 Biggest Movers From Wednesday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
Detecting Early Cancer Screening Stocks At An Early Stage Is Critical
If you're going to get cancer, you’re going to want to detect it early. While we’ve come a long way, baby, when it comes to treating terrible maladies like lung... 
Via Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force... 
Via FinancialNewsMedia
Guardant Health to Participate in the 2021 Stifel Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Registers 27% Revenue Growth In Q3, Tops Consensus; Backs FY21 Guidance
Guardant Health Inc (NASDAQ: GH) reported Q3 sales of $94.8 million, +27% Y/Y, beating the Wall Street estimate of $92.64 million. Guardant's Q3 precision oncology... 
Via Benzinga
Guardant Health Inc (GH) Q3 2021 Earnings Call Transcript
GH earnings call for the period ending October 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Guardant Health: Q3 Earnings Insights
Guardant Health (NASDAQ:GH) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:03 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Guardant Health Reports Third Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
From Guardant Health, Inc.
Via Business Wire
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Appoints Myrtle Potter to Its Board of Directors
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
From Guardant Health, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people... 
Via Benzinga
54 Biggest Movers From Friday
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc.... 
Via Benzinga
Why Guardant Health Is Down More Than 14% Friday
Investors aren't fans of an acquisition the diagnostics company is rumored to be considering. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume... 
Via Benzinga
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar... 
Via Benzinga
Investing in These 2 Top Stocks Could Make You a Millionaire Retiree
Both of these companies boast exciting growth prospects. 
Via The Motley Fool
Topics Retirement
Exposures Pension
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA 
Via Benzinga
Return on Capital Employed Insights for Guardant Health
After pulling data from Benzinga Pro it seems like during Q2, Guardant Health's (NASDAQ:GH) reported sales totaled $92.10 million. Despite a 9.48% in earnings, the company posted... 
Via Benzinga
Guardant Health Expands Precision Oncology Offerings
Guardant’s Q2 revenues grew 39% over the year to $92.1 million, ahead of the Street’s forecast by 8.8%. On an adjusted basis, it reported a loss of $0.96 per share, falling below the Street’s estimates... 
Via Talk Markets
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
From Guardant Health, Inc.
Via Business Wire
Guardant Health, inc (GH) Q2 2021 Earnings Call Transcript
GH earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.